La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lunit Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Beomseok Brandon Suh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Apr 19

AMMINISTRATORE DELEGATO

Beomseok Brandon Suh

no data

Mandato

Mr. Beomseok Brandon Suh is Chief Executive Officer of Lunit Inc. He studied medicine in Seoul National University College of Medicine and is a board certified physician in Family Medicine, trained at Seou...

Lunit Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Recent updates

Price target decreased by 42% to ₩58,000

Lunit's Ai for Tuberculosis Detection Tops in 12-Product Comparative Study

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Inc. announced that it expects to receive KRW 171.5 billion in funding from a group of investors

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit Announces Publication of New Study Featuring Lunit SCOPE IO

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

New minor risk - Shareholder dilution

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America

Third quarter 2023 earnings released: ₩948 loss per share (vs ₩1,576 loss in 3Q 2022)

Lunit Inc. Receives U.S. Food and Drug Administration (FDA) 510(K) Clearance for its 3D Breast Tomosynthesis (DBT) Ai Solution, Lunit Insight DBT

Lunit Inc. has completed a Follow-on Equity Offering in the amount of KRW 200.20077 billion.

Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes

New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023

Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Lunit Inc. Provides Revenue Guidance for the Second Half of the Year 2022

AMMINISTRATORE DELEGATO

Mandato